FDA Beats EU On Cancer Drugs, But Not Others, Study Shows

Law360, New York (September 6, 2012, 7:34 PM EDT) -- The U.S. Food and Drug Administration gets new cancer medicines to patients more rapidly than other pharmaceuticals, and the opposite is true for the European Medicines Agency, according to a study published Wednesday that adds to a growing collection of data comparing the two agencies.

The Tufts Center for the Study of Drug Development in Massachusetts examined approvals over the past decade and found that American regulators cleared oncology treatments 10 months quicker than non-oncology pharmaceuticals. On the other hand, the EMA brought cancer drugs to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.